Loading clinical trials...

Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Body Myositis | Clinical Trials | Clareo Health

RECRUITINGEARLY_PHASE1

Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Body Myositis

NCT06479863•Austin Neuromuscular Center

View on ClinicalTrials.gov

Summary

To evaluate the efficacy of Pozelimab/Cemdisiran combination therapy in patients with sIBM

Detailed Description

This is a pilot study of 10 patients to receive Pozelimab 200mg/Cemdisiran 200 mg SC injections every 4 weeks for 104 weeks. SC injections will be administered by the study staff and the patient will be monitored for 30 minutes after the initial first injection. During the remainder of the study, injections can be administered at home by the patient or caregiver after injection training provided by the study staff. Designated persons will be observed to confirm their ability to perform the injections. The dosing window of the study treatment is within ±7 days from the scheduled dose date.

Eligibility

Age

45 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1\. Age ≥45 years to 75 years of age 2. Diagnosed with sIBM based on the ENMC IBM Research Diagnostic Criteria 3. Willing and able to comply with clinic visits and study-related procedures. 4. Provide informed consent signed by the study patient or legally acceptable representative.
•5\. Able to understand and complete study-related questionnaires. 6. Able to ambulate at least 20 ft/6 meters with or without assistive device Once arising from the chair, the participant may use any walking device, i.e. walker/frame, cane, crutches, or braces. They cannot be supported by another person and cannot use furniture or walls for support.
•7\. If female, the subject must be: (a) surgically sterilized via hysterectomy, bilateral oophorectomy, or bilateral tubal ligation. or (b) of childbearing potential and using a birth control method, such as:
••Combined (estrogen and progestogen-containing) hormonal. contraception associated with inhibition of ovulation:
•o Oral
•* Intravaginal
•* Transdermal
•* Progestogen-only hormonal contraception associated with inhibition of ovulation:
•* Oral
•* Injectable
+7 more criteria

Exclusion Criteria

•1\. Other neurological conditions (e.g., hemiplegia post-stroke, Parkinson's Disease) or musculoskeletal conditions (e.g., severe osteoarthritis) causing mobility impairment.
•2\. Any known active malignancy 3. Significant illness or history of significant illness that, in the investigator's opinion, may adversely affect the patient's participation in this study.
•4\. Any previous treatment with a complement inhibitor 5. History of meningococcal disease 6. No documented meningococcal and pneumococcal vaccination within 5 years prior to screening visit unless vaccination will be administered during the screening period and prior to initiation of study treatment.
•7\. Known contraindication to meningococcal (group ACWY conjugate and group B vaccines) and pneumococcal vaccines.
•8\. Subject unwilling to receive meningococcal and pneumococcal vaccinations. 9. Patients with screening serum ALT levels \>3×ULN and/or total bilirubin \>2×ULN (unless bilirubin elevation is due to suspected Gilbert's syndrome).
•10\. Active or recent systemic infection within 2 weeks prior to Baseline. 11. Pregnant, planning to become pregnant, or lactating female subjects. 12. Treatment with an experimental drug within 30 days or 5 half-lives of the experimental drug.
•13\. Participation in another concurrent interventional clinical trial. 14. Subjects with functional and anatomic asplenia 15. Subjects with positive tests for hepatitis B, hepatitis C, or HIV at screening 16. Presence of active or latent tuberculosis 17. Presence of any other form of myositis or myopathy or myositis overlap with other autoimmune diseases 18. Presence of other autoimmune or autoinflammatory diseases

Locations (2)

Austin Neuromuscular Center

Austin, Texas, United States

Austin Neuromuscular Center

Austin, Texas, United States

Key Dates

Start Date

August 8, 2024

Primary Completion Date

May 30, 2027

Completion Date

August 30, 2027

Last Updated

January 16, 2026

Enrollment

ESTIMATED participants

Conditions

Sporadic Inclusion Body Myositis (sIBM)Idiopathic Inflammatory Myopathies

Interventions

Pozelimab/Cemdisiran

COMBINATION_PRODUCT

Contacts

Yessar Hussain, MD

CONTACT

5129200140 research@austinneuromuscle.com

Emil Hussain, Manager

CONTACT

5129200140 emil@austinneuromuscle.com

A Study of AZD0120 in Autoimmune Diseases

NCT07295847

Systemic SclerosisIdiopathic Inflammatory Myopathies+1 more

View study

RECRUITINGPHASE1

Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune Diseases

NCT07361094

Relapsed/Refractory Systemic Lupus ErythematosusRelapsed/Refractory Systemic Sclerosis+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 16, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Body Myositis

Inclusion Criteria

Exclusion Criteria

A Study of AZD0120 in Autoimmune Diseases

Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune Diseases

AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.

Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System

Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases

Study of Families With Twins or Siblings Discordant for Rheumatic Disorders